> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-13/
- Published: 2020-03-15T12:00:00.000Z
- Updated: 2026-09-14T16:07:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140199

**AmerisourceBergen** has agreed to acquire independent drug wholesaler **H. D. Smith** for $815 million. Founded in 1954, H. D. Smith has 10 drug distribution centers across the U.S. It provides full-line distribution of brand, generic and specialty drugs.

**Orig3n**, a Boston-based biotech, has acquired **Interleukin Genetics**’ CLIA laboratory and its assets. Interleukin Genetics’ technology will be integrated into Orig3n’s DNA test business. The automated genotyping lab is fully-licensed for testing in all 50 U.S. states and is capable of processing over one million samples per year.

Private investment firm **SK Capital** has acquired **Perrigo**’s active pharmaceutical ingredients (API) business, which will be renamed **Wavelength Pharmaceuticals.** The company will now have primary operations located in Israel and supporting functions in the U.S. and India. It provides products that are made with its specialized manufacturing capabilities, including cytotoxic, steroid and high potency products.

Medical-device repair company **Alpha Source** has completed its acquisition of imaging system developer **BC Technical**. The transaction will expand Alpha Source’s ultrasound and bone density equipment service to include maintenance services and refurbished equipment for CT, MRI and molecular scans. Earlier this year, Alpha Source purchased **Medical Optics**, which repairs scopes, cameras and surgical tools.

Montreal-based artificial intelligence company **Imagia** has completed its acquisition of medical imaging firm **Cadens Medical Imaging** for an undisclosed amount. Cadens develops and markets FDA and CE-Marked medical imaging software products designed for oncology. Imagia said it plans to integrate its technologies with imaging products to accelerate development of biomarker discovery processes.